Interestingly, very recently, ACLY has been reported as a critical epigenetic regulator that promotes renal injury in obesity and type 2 diabetes [76,77], while other researchers have used two independent mouse models of kidney fibrosis to demonstrate that the AKT-dependent modulation of this enzyme is involved in kidney fibrogenesis and ECM deposition [78]. Here, ACLY is linked to type 2 diabetes mellitus.